Compare Aurobindo Pharma with NEULAND LABS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs NEULAND LABS - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA NEULAND LABS AUROBINDO PHARMA/
NEULAND LABS
 
P/E (TTM) x 19.6 50.5 38.7% View Chart
P/BV x 4.2 3.8 110.7% View Chart
Dividend Yield % 0.2 0.1 263.2%  

Financials

 AUROBINDO PHARMA   NEULAND LABS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
NEULAND LABS
Mar-20
AUROBINDO PHARMA/
NEULAND LABS
5-Yr Chart
Click to enlarge
High Rs830754 110.1%   
Low Rs527247 213.1%   
Sales per share (Unadj.) Rs333.9594.5 56.2%  
Earnings per share (Unadj.) Rs40.412.6 319.5%  
Cash flow per share (Unadj.) Rs51.837.0 139.8%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.40.4 92.2%  
Book value per share (Unadj.) Rs237.1553.4 42.8%  
Shares outstanding (eoy) m585.9112.83 4,566.7%   
Bonus / Rights / Conversions ESOP--  
Price / Sales ratio x2.00.8 241.4%   
Avg P/E ratio x16.839.6 42.4%  
P/CF ratio (eoy) x13.113.5 97.0%  
Price / Book Value ratio x2.90.9 316.5%  
Dividend payout %6.215.8 39.1%   
Avg Mkt Cap Rs m397,5696,421 6,191.9%   
No. of employees `00017.91.3 1,392.7%   
Total wages/salary Rs m25,8491,236 2,092.1%   
Avg. sales/employee Rs Th10,956.95,949.4 184.2%   
Avg. wages/employee Rs Th1,447.7963.8 150.2%   
Avg. net profit/employee Rs Th1,324.3126.4 1,047.5%   
INCOME DATA
Net Sales Rs m195,6367,627 2,565.0%  
Other income Rs m1,55339 3,997.9%   
Total revenues Rs m197,1897,666 2,572.3%   
Gross profit Rs m39,5191,019 3,878.7%  
Depreciation Rs m6,680313 2,135.4%   
Interest Rs m2,626216 1,217.3%   
Profit before tax Rs m31,767529 6,002.9%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,269367 1,979.9%   
Profit after tax Rs m23,645162 14,588.5%  
Gross profit margin %20.213.4 151.2%  
Effective tax rate %22.969.4 33.0%   
Net profit margin %12.12.1 568.8%  
BALANCE SHEET DATA
Current assets Rs m153,6455,152 2,982.3%   
Current liabilities Rs m120,4293,576 3,367.4%   
Net working cap to sales %17.020.7 82.2%  
Current ratio x1.31.4 88.6%  
Inventory Days Days135105 128.7%  
Debtors Days Days6491 70.1%  
Net fixed assets Rs m103,9093,969 2,618.3%   
Share capital Rs m586129 454.2%   
"Free" reserves Rs m138,3226,971 1,984.4%   
Net worth Rs m138,9087,100 1,956.6%   
Long term debt Rs m1,800774 232.6%   
Total assets Rs m264,54412,310 2,149.0%  
Interest coverage x13.13.5 379.3%   
Debt to equity ratio x00.1 11.9%  
Sales to assets ratio x0.70.6 119.4%   
Return on assets %9.93.1 323.6%  
Return on equity %17.02.3 745.6%  
Return on capital %23.89.5 251.9%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,3165,187 1,876.3%   
Fx outflow Rs m40,5891,593 2,548.3%   
Net fx Rs m56,7273,594 1,578.4%   
CASH FLOW
From Operations Rs m16,220573 2,828.8%  
From Investments Rs m-28,768-487 5,909.7%  
From Financial Activity Rs m19,191-55 -35,019.3%  
Net Cashflow Rs m6,65633 20,418.4%  

Share Holding

Indian Promoters % 54.1 36.3 149.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 63.7 12.5%  
FIIs % 27.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 63.7 16.0%  
Shareholders   69,601 12,705 547.8%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex Zoomed 613 Points Today(Closing)

Indian share markets extended gains as the session progressed and ended on a strong note.

Related Views on News

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


May 18, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS